-

Verantos Named to Inc. 5000 List for the Fourth Consecutive Year

Global leader in high-validity real-world evidence for life sciences continues strong growth

PALO ALTO, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence (RWE) for the life sciences, marks its fourth consecutive appearance on the Inc. 5000, ranking No. 2405 on the most prestigious list of the fastest-growing private companies in America. The list provides a data-driven snapshot of the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia.

“Our continued recognition on the Inc. 5000 list of the fastest-growing private companies in America reflects the importance of high-validity real-world evidence to life sciences organizations and patients,” said Dan Riskin, CEO of Verantos.

Share

“Our continued recognition on the Inc. 5000 list of the fastest-growing private companies in America reflects the importance of high-validity real-world evidence to life sciences organizations and patients,” said Dan Riskin, CEO of Verantos. “We’re proud to be once again counted among the nation’s most innovative companies.”

This year’s Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years.

“Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company’s tenacity and clarity of vision,” says Mike Hofman, editor-in-chief of Inc. “These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn’t just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.”

About the Inc. 5000

Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.

About Inc.

Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.

About Verantos

Verantos is the global leader in high-validity real-world evidence at scale. By applying artificial intelligence to the complete patient record, Verantos enables life sciences organizations to generate high-validity evidence across therapeutic areas with measured accuracy, completeness, and traceability. Credible evidence accelerates clinical development, market access, medical affairs, pharmacovigilance, and regulatory initiatives. For more information, visit Verantos.com or follow us on LinkedIn.

Contacts

Verantos


Release Versions
Hashtags

Contacts

Social Media Profiles
More News From Verantos

Verantos to Present Practical Approaches in High-Validity Real-World Evidence Generation at ISPE’s 41st Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence at scale, announced today that it will present practical approaches for generating high-validity real-world evidence (RWE) at the International Society for Pharmacoepidemiology (ISPE) 41st Annual Meeting in Washington, D.C. CEO Dan Riskin will share approaches to achieve fit-for-use RWD based on real-world learnings from large pharma collaborations and the FDA-sponsored Verantos-led TRUST and V...

Verantos-led Study in JAMA Network Open Demonstrates a Defined Approach to Measure and Optimize Data Reliability

PALO ALTO, Calif.--(BUSINESS WIRE)--Verantos, the global leader in high-validity real-world evidence at scale, today announced the publication “Implementing Accuracy, Completeness, and Traceability for Data Reliability” in JAMA Network Open. The study, written in collaboration with a consortium of academic and industry leaders, proposes a reproducible framework for measuring and optimizing the reliability of real-world data (RWD). In 2024, the FDA published the final guidance document “Real-Wor...

Verantos Ranked Number 319 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

PALO ALTO, Calif.--(BUSINESS WIRE)--Verantos today announced it ranked 319 on the Deloitte Technology Fast 500. Verantos is the only RWE company on the list for the second year in a row....
Back to Newsroom